Physician profile
Daphna Shalom
NPI 1801292925
$2,114.25
in general payments reported to CMS, 2019-2025
14 companies · $277 in 2025
The $277 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $344 · 2022: $799 · 2023: $362 · 2024: $332 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $971.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $971.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $588.54 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $525.63 | 2022-2023 | Austedo, Austedo Xr |
| Abbvie INC. | $523.42 | 2021-2025 | |
| Galderma Laboratories, L.P. | $163.37 | 2022-2025 | |
| Revance Therapeutics, INC. | $61.72 | 2025 | Daxxify |
| Neurelis, INC. | $60.54 | 2023-2024 | Valtoco |
| Mallinckrodt Hospital Products INC. | $32.52 | 2021 | |
| Sk Life Science, INC. | $32.06 | 2023 | |
| Lundbeck LLC | $28.97 | 2024 | Vyepti |
| Otsuka America Pharmaceutical, INC. | $24.77 | 2025 | Rexulti |
| Tanabe Pharma America, INC. | $23.13 | 2023 | |
| Lilly USA, LLC | $20.75 | 2023 | Amyvid |
| Solta Medical, A Division of Bausch Health US, LLC | $17.61 | 2024 | Clear+Brilliant |
| Ucb, INC. | $11.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daphna Shalom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.